to determine if there is induction of endothelial RAGE in pterygium.
METHODS

Patients and specimens:
Pterygium specimens were obtained from 25 patients during pterygium surgery at the King Khaled Eye Specialist Hospital (KKESH). Patients were in good health and ranged from 17 to 85 years of age, with 18 males and 7 females (Table 1) . Pterygium specimens were obtained during pterygium surgery at the King Khaled Eye Specialist Hospital (KKESH). All patients underwent pterygium excision, rotational conjunctival flap, application of (mitomycin C) MMC 0.2 mg/ml × 1 min. Two patients required amniotic membrane transplantation (AMT) to cover bare sclera. In the same patients, 1.5 × 1.5 mm conjunctiva specimens were obtained from the superior temporal quadrant of bulbar conjunctiva during the surgery. The tissues were fixed in 10% formalin and embedded in paraffin. Clinical details pertaining to the study patients are described in Table 1 . The study adhered to the tenets of the Declaration of Helsinki. The study protocol was approved by the Institutional Review Boards at the Johns Hopkins School of Medicine and the King Khaled Eye Specialist Hospital, and study participants gave informed consent to the treating surgeon.
Immunohistochemistry: Deparaffinized sections were boiled in 1× target retrieval solution (Dako, Capenteria, CA) for 20 min. Endogenous peroxidase activity was quenched by treating samples with 3% hydrogen peroxide for 5 min. After blocking in 5% normal goat serum diluted in PBS (1X; 155 mM NaCl, 1.06 mM KH 2 PO 4 , 2.97 mM Na 2 HPO 4 -7H 2 O, pH 7.4), the sections were incubated with anti-RAGE antibody (1:125, Abcam, Cambridge, MA), anti-CD31 antibody (1:100, Abcam), or the isotype-and concentration-matched normal immunoglobulin G (IgG) control (Abcam) overnight at 4 °C. After three washes with PBST (PBS plus 0.1% Tween-20), the sections were then incubated with the secondary biotinylated 
RESULTS
RAGE expression and localization in pterygium and conjunctiva:
We first investigated the localization of RAGE expression in pterygium, with specific interest in whether RAGE is expressed in vascular endothelial cells. RAGE expression in pterygium and conjunctival specimens was evaluated with immunohistochemical staining. In pterygium and conjunctiva, RAGE expression was detected in the epithelial layer in all specimens ( Figure 1 ). In addition, RAGE was expressed in several cell types in the stroma, including fibroblasts, inflammatory cells, and vascular endothelial cells, as indicated by corresponding staining with the endothelial cell marker CD31/PECAM-1 ( Figure 1 ). Of note, RAGE expression was consistently found in vascular endothelial cells in pterygium tissue, although to varying degrees ( Figure 1 ; Table 2 ).
Induction of RAGE expression in vascular endothelial cells in pterygium:
In the epithelium, there was no obvious difference in the level of RAGE expression between the conjunctiva and pterygium tissue. In light of the importance of RAGE in the activation of endothelium during inflammation [8] , we were particularly interested in determining whether RAGE is induced in endothelial cells in pterygium specimens. For this purpose, we examined endothelial RAGE expression in 25 cases of pterygium and their corresponding normal conjunctiva. RAGE expression was graded by two independent observers ( Table 2 ). As shown in Among 20 primary pterygium cases, in 16 patients (80%), the RAGE levels were increased in the vasculature compared to the corresponding conjunctiva (Table 2; Figure  2 ). In five recurrent pterygium cases, three cases exhibited increased expression of endothelial RAGE (Table 2; Figure  3) . Because of the small number of recurrent pterygium cases, the correlation between RAGE expression and disease stage (primary versus recurrent) could not be determined.
DISCUSSION
Inf lammation is an important pathogenic process in pterygium, and multiple proinflammatory molecules have been identified in pterygium tissue. Vascular endothelial cells play an active role in the inflammatory process, interacting with leukocytes to promote inflammation. Interestingly, endothelial cell activation per se has received relatively little attention in pterygium progression. Our group is interested in identifying potential mechanisms of EC activation in pterygium. Given the known role of RAGE in ECs in multiple systemic diseases, we hypothesized that RAGE expression is induced in ECs in pterygium.
We first examined cellular localization of RAGE in pterygium and conjunctiva specimens. We detected RAGE expression in the epithelial layer and specific cell types in the stroma, including vascular endothelial cells, fibroblasts, and inflammatory cells. Although RAGE expression has not been hitherto studied in conjunctiva or pterygium, our finding for the epithelial expression of RAGE is consistent with previous reports of RAGE in other tissue, including epithelial cells in the colon [10] , lung [11] , and notably in skin [12] .
Given the critical role for RAGE in endothelial cell activation during inflammation [8] , we specifically scrutinized RAGE expression in the vascular endothelium. In our series, we found that pterygium tissue consistently exhibited expression of RAGE in endothelial cells and that endothelial RAGE was largely, albeit not uniformly, induced in ECs in pterygium compared to the control conjunctiva. This suggests that RAGE could be an important molecule that contributes to the inflammatory process and progression in pterygium.
The potential importance of endothelial RAGE induction in pterygium is highlighted by present knowledge of the role of RAGE in systemic inflammation. Inflammation and vascular proliferation are major factors in pterygium [1] [2] [3] . From this perspective, it is clear that vascular endothelial cells are a significant cell type in pterygium pathogenesis. ECs play an active role in recruiting leukocytes to local tissue sites during inflammation, and activated ECs release cytokines and chemokines involved in the inflammatory process [4, 8] . In this light, endothelial RAGE activation could represent an important mechanism for pterygium progression. RAGE upregulation and activation are an important mechanism by which endothelial cells amplify the overall inflammatory response [9] . RAGE is induced in vascular ECs during injury and inflammation, and migration of leukocytes across the endothelium is mediated by RAGE. The ligand-RAGE interaction triggers the activation of NF-kB in endothelial cells, with subsequent cellular release of cytokines including TNF-α [7] . Interestingly, ligand-RAGE interaction generates reactive oxygen species [13] , providing further relevance for RAGE given the role of oxidative stress in pterygium [2] . Finally, it is of interest that RAGE has been implicated in inflammation-associated angiogenesis, for instance, in a mouse model of laser-induced choroidal neovascularization, in which RAGE deficiency resulted in a significant impairment in pathologic angiogenesis [14] .
To further elucidate the biology of RAGE in pterygium, it will be of interest to identify possible ligands involved in RAGE signaling in activated endothelium. Since RAGE binds multiple different ligands, it is considered a pattern recognition receptor (PRR), recognizing a structural motif [8] . RAGE has multiple ligands, including AGEs, members of the S100/calgranulin family, HMGB1, and Mac1 [15] . Multiple members of the S100 family are upregulated in pterygium tissue [16, 17] and in the tear fluid of patients with pterygium [18] . To our knowledge, other potential ligands for RAGE have not yet been reported in pterygium tissue.
The current study relied on immunohistochemistry and a semiquantitative scoring system to evaluate the expression of endothelial RAGE in pterygium and conjunctiva. This approach has been used by multiple investigators for studies in pterygium [19] [20] [21] [22] as well as other ocular conditions including age-related macular degeneration [23] and diabetic retinopathy [24] . This semiquantitative approach has limitations, including reduced precision of results and a potential susceptibility to grader bias, compared to quantitative approaches such as western blotting and quantitative RT-PCR (qRT-PCR). Since the current study is focused on the expression of RAGE specifically in endothelial cells, western blotting was not a viable approach. In theory, qRT-PCR could be considered, but this would prohibitively require laser-capture microdissection of very large numbers of individual blood vessels in cryopreserved sections for each specimen. For the semiquantitative immunohistochemistry (IHC) approach, which was used in the current study, two helpful strategies have been used by many investigators, including two or more independent evaluators as well as a masked grading approach [20, 22] , and we incorporated these approaches in the current study.
The presence and induction of endothelial RAGE in primary and recurrent pterygium indicate RAGE could potentially contribute to promoting pterygium progression and suggests that RAGE might represent a therapeutic target. Suppression of RAGE has been shown to prevent progression of some systemic disease processes in experimental models, and RAGE inhibition is actively being investigated for treating various systemic disease processes, with strategies including soluble RAGE species as well as small molecule inhibitors of RAGE [8] . The potential amenability of pterygium to local treatment approaches including topical delivery suggest RAGE targeting as an attractive pharmacologic strategy for this disease condition. 
